PDCD1 and cancer: In recent years, immunotherapies targeting the T-cell immune checkpoint receptor PD-1, or its ligand PD-L1 and cytotoxic T lymphocyte-associated protein 4 (CTLA-4), have led to significant improvements in some cancer prognosis.